In this article:

Guardant Health (GH) Gets a Buy Rating from Leerink Partners

In this article:
In this article:

In a report issued on April 4, Puneet Souda from Leerink Partners assigned a Buy rating to Guardant Health (GHResearch Report). The company’s shares closed last Tuesday at $75.03.

According to TipRanks.com, Souda is ranked 0 out of 5 stars with an average return of -3.5% and a 41.0% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardant Health with a $123.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Guardant Health’s market cap is currently $7.88B and has a P/E ratio of -19.31.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.

Read More on GH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed